Clinicians’ Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, “Real-Life”, Case-Control Study-Reference-Cited by-同舟云学术

Clinicians’ Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, “Real-Life”, Case-Control Study

Published:2021-12 Issue:4 Volume:20 Page:318-325
ISSN:1533-0028
Container-title:Clinical Colorectal Cancer
language:en
Short-container-title:Clinical Colorectal Cancer

Author:

Parisi Alessandro^ORCID,Porzio Giampiero,Cannita Katia,Venditti Olga,Avallone Antonio,Filippi Roberto,Salvatore Lisa,Tortora Giampaolo,Ribelli Marta,Nigro Olga,Gelsomino Fabio^ORCID,Spallanzani Andrea^ORCID,Zurlo Valeria,Leo Silvana,Dell'Aquila Emanuela,Claudia Fulgenzi^ORCID,Lombardi Pasquale,Keränen Susana Roselló^ORCID,Aimar Giacomo,Depetris Ilaria,Giampieri Riccardo,Morelli Cristina,De Tursi Michele^ORCID,Tinari Nicola,Di Pietro Francesca Romana,De Galitiis Federica,Zanaletti Nicoletta,Troiani Teresa,Vitale Pasquale,Garajova Ingrid,Ghidini Michele,Spinelli Gian Paolo^ORCID,Zoratto Federica,Roberto Michela,Ierino Debora,Petrillo Angelica^ORCID,D'Orazio Carla,Ficorella Corrado,Cortellini Alessio

Publisher

Elsevier BV

Subject

Gastroenterology,Oncology

Reference30 articles.

1. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer;Van Cutsem;Ann Oncol,2016

2. Treatment of Patients With Late-Stage Colorectal Cancer: ASCO Resource-Stratified Guideline;Chiorean;JCO Glob Oncol,2020

3. Linee guida AIOM TUMORI DEL COLON – Edizione 2020. Available at https://www.aiom.it/wp-content/uploads/2020/10/2020_LG_AIOM_Colon.pdf

4. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials;Arnold;Ann Oncol,2017

5. Impact of primary tumor location in patients with RAS wild-type metastatic colon cancer treated with first-line chemotherapy plus anti-EGFR or anti-VEGF monoclonal antibodies: a retrospective multicenter study;Grassadonia;J Cancer,2019

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunotherapeutic strategies for the treatment of colorectal cancer;Principles of Immunotherapy Breast and Gastrointestinal Cancers;2025

2. Application of sintilimab combined with anlotinib hydrochloride in the clinical treatment of microsatellite stable colorectal cancer;World Journal of Gastrointestinal Oncology;2023-11-15

3. Conversion Strategy in Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer Patients with Unresectable Liver-Limited Disease: A Multicenter Cohort Study;Cancers;2022-11-09

4. Post-induction Strategies in Metastatic Colorectal Cancer Patients Treated With First-Line Anti-EGFR-Based Treatment: A Systematic Review and Meta-Analysis;Clinical Colorectal Cancer;2022-09

5. Primary versus secondary antiemetic prophylaxis with NK1 receptor antagonists in patients affected by gastrointestinal malignancies and treated with a doublet or triplet combination regimen including oxaliplatin and/or irinotecan plus fluoropyrimidines: A propensity score matched analysis;Frontiers in Oncology;2022-08-12